Onco Actu du 25 septembre 2017

	1. Biologie
Metastatic breast cancer affects bone mineral before spreading [Cornell University] “The goal now is to really understand why these changes are happening,” she said. “Why and how do tumor cells change these properties in bone, prior to the formation of metastasis, and how is that then functionally relevant to seeding a new tumor?”
	2.6 Etiologie - Environnement
France reaffirms opposition to license renewal for weedkiller glyphosate [Reuters] “The European Commission has proposed renewing its approval for glyphosate for another 10 years. This is far too long, given the concerns that remain over this product, and France will vote against the proposal, as clearly laid out previously in July,” Prime Minister Edouard Philippe said in a statement.
	3.3 Prévention - Vaccins
The HPV Vaccine Gains Ground Among U.S. Teenagers [NY Times] Sixty percent of adolescents received one or more doses of the HPV vaccine in 2016, an increase of 4 percentage points from 2015, researchers found. About a decade ago, the figure was less than 30 percent.
	4.2 Dép., diag. & prono. - Génome
DNA start-ups attract cash from venture funds [Financial Times] In the past month, start-ups building clinically useful software and data-mining applications have received a windfall in venture funding. They offer services as varied as cancer screening and diagnosis, epidemic monitoring and fertility treatments.
	5.12.1 Immunothérapies - partenariats
AbbVie pairs up another ADC cancer drug with Bristol-Myers Squibb's Opdivo [FierceBiotech] In the case of ABBV-399 (telisotuzumab vedotin), the ADC is designed to bind to and destroy cells that overexpress c-Met. The drug has shown activity against c-Met-positive NSCLC in early-stage trials.
AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors [AbbVie] A Phase 1b clinical study is underway that includes evaluating the potential of combining Opdivo, which is designed to alleviate immune suppression, with ABBV-399 to explore the tolerability and potential efficacy of the combination in subjects with advanced c-Met overexpressing NSCLC who failed one prior line of chemotherapy.
	5.12.6 Immunothérapies - AMM
Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy [BMS] Opdivo is the first Immuno-Oncology agent anywhere in the world to receive approval for unresectable advanced or recurrent gastric cancer based on a Phase 3 study.
Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib [BMS] In the CheckMate -040 trial, 14.3%* (95% CI: 9.2-20.8; 22/154) of patients responded to treatment with Opdivo.
Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer [Roche] TECENTRIQ is already approved in the USA and in several other countries for people with metastatic NSCLC – and for people with locally advanced or mUC who are not eligible for cisplatin chemotherapy, or who have had disease progression during or following platinum-containing therapy.
FDA grants accelerated approval to pembrolizumab for advanced gastric cancer [FDA] For the 143 patients with tumors expressing PD-L1 and who were either MSS or had unknown MSI or dMMR status, the objective response rate was 13.3% (95% CI: 8.2, 20.0); 1.4% had complete responses and 11.9% had partial responses.
Roche cancer immunotherapy Tecentriq wins EU approval [Reuters] Roche is counting on the immunotherapy to help offset the loss of sales from biologic cancer drugs facing cut-throat competition from so-called biosimilar rivals.
	5.12.8 Immunothérapies - Economie
Gene Therapy Holds Great Promise, But Big Price [Express Scripts] Ideas on the table include paying for a treatment over time, establishing insurer risk pools and financing one-time payments. A successful model must address patients who change insurers or employers, and tracking their health outcomes over time to ensure payments aren’t being made if the treatment stops being effective.
How to cover Novartis’ $475K CAR-T drug Kymriah? A ‘new payment model’ is the only way, Express Scripts says [FiercePharma] Miller singles out two approved gene therapies in Europe that he believes offer a warning of what can go wrong with high-priced gene therapies.
	5.3 Traitements - FDA, EMA, NICE...
FDA Disputes Article Highlighting Lackluster Oversight of Postmarketing Studies [RAPS] A paper appearing in the New England Journal of Medicine on Thursday argues that the US Food and Drug Administration (FDA) is not doing enough to ensure drugmakers complete postmarketing studies required by the agency at the time their drugs are approved.
	5.3.4 Traitements - AMM (FDA, EMA)
FDA Expands Approval of Fulvestrant for Advanced Breast Cancer [NCI] The primary endpoint of the trial was median progression-free survival. Patients in the fulvestrant group had a median progression-free survival of 16.6 months, versus 13.8 months in the anastrozole group.
	6. Lutte contre les cancers
To advance medicine’s future, the NIH tries to win the trust of communities mistreated in the past [STAT] The National Institutes of Health would like six vials of your blood, please. Its scientists would like to take a urine sample, measure your waistline, and have access to your electronic health records and data from the wearable sensor on your wrist. And if you don’t mind sharing, could they have your Social Security number?
	6.1 Observation
Forgoing Chemotherapy Linked to Worse Survival in Older Patients With Advanced Colon Cancer Who had Dementia [AACR] Chen and colleagues started by performing a retrospective cohort study using SEER-Medicare data for 3,903 adults over the age of 65 with confirmed diagnoses of stage 3 colon cancer and dementia.
	6.4 Médico-éco
Richard Smith: Schopenhauer, the Economist, and cancer [BMJ Blogs] The article makes the almost universal mistake of concentrating on healthcare, failing to recognise that healthcare accounts for only around 10% of the factors that determine how long we live and how much we suffer. But the Economist’s two biggest failings are, firstly and ironically, to hardly consider the economics of it all and, secondly, to think what would happen when cancer was cured.
	6.6 Publications
Few authors choose anonymous peer review, massive study of Nature journals shows [Science] Some 32% of Indian authors and 22% of Chinese authors opted for double-blind review, compared with only 8% of authors from France and 7% from the United States.